Lovenox (enoxaparin sodium) is an antithrombolytic agent also known as low molecular weight heparin (LMWH). Lovenox is FDA approved for use in the prevention of deep vein thrombosis (DVT) after hip, knee, and abdominal surgery. It also has been approved for use with unstable angina and non-Q wave myocardial infarction (MI). Lovenox produces a predictable antithrombolytic response so that serial partial thromboplastin times (PTT) are no longer necessary over a normal course of treatment. However, periodic tests such as complete blood counts (CBC) and stool occult blood tests are recommended during treatment. Caution should be used with patients who have a sensitivity to heparin, pork products, or with active bleeding. Overdose treatment is identical to heparin, using protamine sulfate. For more information on Lovenox check the following sites:
Treatment of DVT
Treatment after Abdominal Surgery
Treatment for Unstable Angina and non-Q wave MI
Company Product Information
References
Drug Facts and Comparisons. January 2000 pg 163-165b.
